Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Core Insights - Vor Bio, a clinical-stage biotechnology company, is focused on transforming the treatment of autoimmune diseases through innovative therapies [3] Stock Options and RSUs - The Compensation Committee granted stock options to purchase 6,959,013 shares and restricted stock units (RSUs) for 1,491,217 shares to seven new employees as part of the Inducement Plan [1] - Stock options have a ten-year term with exercise prices between $2.11 and $2.04 per share, equal to the closing price on grant dates [2] - Both stock options and RSUs will vest over four years, with 25% vesting after 12 months and the remainder vesting monthly or quarterly thereafter, contingent on continued employment [2] Company Overview - Vor Bio is advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development to address serious autoantibody-driven conditions globally [3]